Jim Cramer agrees with UBS: The rally in Johnson & Johnson shares to new highs still has room to run. In a note to clients Wednesday, analysts at UBS raised their price target on the healthcare giant to $320 per share from $280. Their bullish view is based on three factors: (1) Top-line growth inflecting from…
Cardinal Health on Tuesday showed why the healthcare distributor belongs in our portfolio, delivering robust full-year earnings guidance that trumped some imperfections in the final quarter of its fiscal 2026. Revenue for the three months ending June 30 increased nearly 6% year over year to $63.67 billion, missing expectations of $65.03 billion, according to LSEG….
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stocks are choppy on Friday, with the S & P 500 swinging in and out of positive territory. For the week, the S & P 500…
Time to buckle up. Earnings season is returning, and hopes of a durable resolution to the Iran war faced a setback over the weekend, injecting fresh uncertainty into the trading week ahead. Here’s a closer look at the three big things we are watching over the next five days. 1. Iran war: Peace talks between…
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. Stocks fell Tuesday as investors lose hope for a ceasefire that depends on whether U.S. and Iran reach an agreement to reopen the Strait of Hormuz. President Donald Trump threatened…
Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat…
